Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus.

Journal of immunology (Baltimore, Md. : 1950) - 15 Feb 2002

Wang Xiaobo, Huang Weiqing, Mihara Masahiko, Sinha Jayashree, Davidson Anne

Abstract excerpt

Short-term combination therapy with the costimulatory antagonists CTLA4Ig and anti-CD40 ligand induces prolonged suppression of disease onset in New Zealand Black/New Zealand White F(1) systemic lupus erythematosus-prone mice. To determine the mechanism for this effect, 20- to 22-wk-old New Zealand Black/New Zealand White F(1) mice were treated with six doses each of CTLA4Ig and anti-CD40 ligand Ab over 2 wk....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Abatacept
Share to Antibodies, Antinuclear

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Differentiation

Share to CD40 Ligand

Share to Hybridomas

Share to Immunoconjugates

Share to Immunoglobulin Class Switching

Share to Mice, Inbred NZB

Source

Identifiers

PMID: 11823542
DOI: 10.4049/jimmunol.168.4.2046

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus.PMID 11823542Read ↗

Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathwaysSemantic proximity Read ↗

Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody responseSemantic proximity Read ↗

Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.Semantic proximity Read ↗

Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus.Semantic proximity Read ↗

Production of High Affinity Autoantibodies in Autoimmune New Zealand Black/New Zealand White F1 Mice Targeted with an Anti-DNA Heavy ChainSemantic proximity Read ↗

The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus.Semantic proximity Read ↗

CD4+ T lymphocytes with constitutive CD40 ligand in preautoimmune (NZB x NZW)F1 lupus-prone mice: phenotype and possible role in autoreactivity.Semantic proximity Read ↗

Treatment of Murine Lupus with CTLA4IgSemantic proximity Read ↗

Blockade of OX40/OX40L signaling using anti‐OX40L alleviates murine lupus nephritisSemantic proximity Read ↗

CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.Semantic proximity Read ↗

Constitutive OX40/OX40 Ligand Interaction Induces Autoimmune-Like DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.